A new analysis has demonstrated that transcatheter aortic valve implantation (TAVI) is likely to be a cost-effective alternative to medical management in patients with severe aortic stenosis who are ineligible for surgical aortic valve replacement. The decision analytical model used in the study assessed costs and benefits over a 10-year timeframe. The incremental cost-effectiveness ratio for TAVI was ∼£16,100 per quality-adjusted life year gained, which is below the threshold range (£20,000–£30,000 over 7 years) used by the UK National Institute for Health and Clinical Excellence to determine 'cost-effectiveness'.